SCHEMBL3564565

SCHEMBL3564565

O=C(O)N1CCC(n2ccnc2-c2ccccc2)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.43
LMNA P02545 1/20 0.39
ACACB O00763 1/20 0.38
ACACA Q13085 1/20 0.38
EPHX2 P34913 2/20 0.38
ACHE P22303 3/20 0.38
HTR2B P41595 2/20 0.38
HDAC4 P56524 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
EPHX1 P07099 1/20 0.37
USP2 O75604 1/20 0.37
ABCC9 O60706 1/20 0.37
PLAA Q9Y263 1/20 0.36
F10 P00742 1/20 0.36
CYP46A1 Q9Y6A2 1/20 0.36
HTR2A P28223 1/20 0.36
HRH1 P35367 1/20 0.36
HCRTR1 O43613 1/20 0.36
HCRTR2 O43614 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19308657 0.88 F10 (0.43) HTR2BABCC9F10
SCHEMBL3560855 0.84 GPR119 (0.53) EGFRSRC
SCHEMBL28226097 0.83 ESR1 (0.41) ESR1LMNAABCC9PLAAEGFR
SCHEMBL16828068 0.81 PDK2 (0.53)
SCHEMBL16828064 0.81 PDK2 (0.53)
SCHEMBL27761911 0.79 LMNA (0.43) ESR1LMNAABCC9EGFRSRC
SCHEMBL6039509 0.77 NSD3 (0.43) ABCC9EGFRSRC
Trifluoroacetic Acid SCHEMBL16827760 0.76 NSD3 (0.39) ESR1LMNAL3MBTL1
Hydrochloric Acid SCHEMBL8484921 0.76 DRD4 (0.56)
SCHEMBL5429002 0.73 KDM5A (0.47) ACHEL3MBTL3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9751861-B2 N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase MERCK PATENT GMBH (DE) 2017-09-05 US disclosed
EP-2010525-B1 Diketo-piperazine and piperidine derivatives as antiviral agents BRISTOL MYERS SQUIBB CO (US) 2013-08-28 EP disclosed
US-7807676-B2 Diketo-Piperazine and Piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-7807671-B2 Diketo-piperazine and piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-06-12 US disclosed
US-20070249579-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS EIF2AK2, DCK, MAVS ESR1 4673/4885LMNA 4368/4885ACACB 2850/4885
US-20070249579-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS EIF2AK2, DCK, MAVS ESR1 4673/4885LMNA 4368/4885ACACB 2850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.